trending Market Intelligence /marketintelligence/en/news-insights/trending/E5kmtD-Hglg4Dgt0UXaeqA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

ChenGuang Biotech swings to profit in Q4

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


ChenGuang Biotech swings to profit in Q4

ChenGuang Biotech Group Co. Ltd. said its normalized net income for the fourth quarter came to 4 fen per share, compared with a loss of 2 fen per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 12.9 million yuan, compared with a loss of 7.1 million yuan in the prior-year period.

The normalized profit margin climbed to 0.5% from negative 2.2% in the year-earlier period.

Total revenue grew 6.8% on an annual basis to 346.8 million yuan from 324.7 million yuan, and total operating expenses rose year over year to 324.7 million yuan from 321.2 million yuan.

Reported net income increased year over year to 19.5 million yuan, or 6 fen per share, from 9.6 million yuan, or 3 fen per share.

For the year, the company's normalized net income totaled 12 fen per share, a gain from 3 fen per share in the prior year.

Normalized net income was 36.4 million yuan, a rise from 9.0 million yuan in the prior year.

Full-year total revenue grew 5.0% from the prior-year period to 1.27 billion yuan from 1.21 billion yuan, and total operating expenses increased year over year to 1.20 billion yuan from 1.18 billion yuan.

The company said reported net income rose on an annual basis to 68.9 million yuan, or 23 fen per share, in the full year, from 22.4 million yuan, or 7 fen per share.

As of March 28, US$1 was equivalent to 6.48 yuan.